Addex Q1 FY26 net loss widens to CHF 1.71 million; operating loss narrows to CHF 480,000
PUBT · 21h ago
Share
Listen to the news
- Addex reported a Q1 net loss of CHF 1.71 million, widening from CHF 1.47 million a year earlier.
- Operating loss narrowed to CHF 480,000 from CHF 606,000, as R&D fell to CHF 36,000 from CHF 156,000.
- Cash and cash equivalents dropped to CHF 935,000 from CHF 2.83 million, while shareholders’ equity slid to CHF 3.29 million from CHF 8.3 million.
- CEO Tim Dyer said spin-out Neurosterix is on track to complete the Phase 1 study of NTX-253 in July, with data expected later in summer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250100PRIMZONEFULLFEED1001209485) on June 25, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved